Low-dose subcutaneous alemtuzumab is a safe and effective treatment for chronic acquired pure red cell aplasia
Three patients with pure red cell aplasia, with or without co-existing large granular lymphocytic leukaemia, who remained transfusion-dependent despite treatment with established first-line therapy, were treated with low-dose subcutaneous alemtuzumab 15 mg twice to thrice per week, for 3 to 4 weeks....
Gespeichert in:
| Veröffentlicht in: | Hong Kong medical journal = Xianggang yi xue za zhi 2013-12, Vol.19 (6), p.549-552 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 552 |
|---|---|
| container_issue | 6 |
| container_start_page | 549 |
| container_title | Hong Kong medical journal = Xianggang yi xue za zhi |
| container_volume | 19 |
| creator | Chow, Jason K W Chan, T K |
| description | Three patients with pure red cell aplasia, with or without co-existing large granular lymphocytic leukaemia, who remained transfusion-dependent despite treatment with established first-line therapy, were treated with low-dose subcutaneous alemtuzumab 15 mg twice to thrice per week, for 3 to 4 weeks. The mean response time was 17 days compared with a response time of at least 61 days on standard first-line therapy. There were no serious side-effects and the mean duration of remission was 13 months. Low-dose subcutaneous alemtuzumab is a safe and effective treatment for pure red cell aplasia and further trials should be conducted to compare the long-term effectiveness of this treatment with conventional therapy. |
| doi_str_mv | 10.12809/hkmj133798 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1465865934</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2786942262</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-39844d3f45c50ac47716a706474da462481627cb8fb3e720d00817255f8cb39b3</originalsourceid><addsrcrecordid>eNpdkUtLAzEUhYMotlZX7iXgRpDRvCbJLKX4goIbXQ-ZzA2dOq8mE0V_vVNbFVzde-HjcO45CJ1SckWZJtn18rVZUc5VpvfQlDEmE62I2kdTSphImCJ6go5CWBHCdJqRQzRhglMipZiidtG9J2UXAIdY2DiYFroYsKmhGeJnbEyBq_HEwTjApi0xOAd2qN4ADx7M0EA7YNd5bJe-ayuLjV3HykOJ--gBbxYLdY1NX5tQmWN04Ewd4GQ3Z-jl7vZ5_pAsnu4f5zeLxPJUDAnPtBAldyK1KTFWKEWlUUQKJUojJBOaSqZsoV3BQTFSEqKpYmnqtC14VvAZutjq9r5bRwhD3lRhY2T7X06FTLVMMy5G9Pwfuuqib0d3OVNaZmIMlI3U5ZayvgvBg8t7XzXGf-SU5N815H81jPTZTjMWDZS_7E_u_Au3CoKY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2786942262</pqid></control><display><type>article</type><title>Low-dose subcutaneous alemtuzumab is a safe and effective treatment for chronic acquired pure red cell aplasia</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Chow, Jason K W ; Chan, T K</creator><creatorcontrib>Chow, Jason K W ; Chan, T K ; Department of Oncology, Charing Cross Hospital, Fulham Palace Road, London, United Kingdom</creatorcontrib><description>Three patients with pure red cell aplasia, with or without co-existing large granular lymphocytic leukaemia, who remained transfusion-dependent despite treatment with established first-line therapy, were treated with low-dose subcutaneous alemtuzumab 15 mg twice to thrice per week, for 3 to 4 weeks. The mean response time was 17 days compared with a response time of at least 61 days on standard first-line therapy. There were no serious side-effects and the mean duration of remission was 13 months. Low-dose subcutaneous alemtuzumab is a safe and effective treatment for pure red cell aplasia and further trials should be conducted to compare the long-term effectiveness of this treatment with conventional therapy.</description><identifier>ISSN: 1024-2708</identifier><identifier>EISSN: 2226-8707</identifier><identifier>DOI: 10.12809/hkmj133798</identifier><identifier>PMID: 24310664</identifier><language>eng</language><publisher>China: Hong Kong Academy of Medicine</publisher><subject>Aged ; Alemtuzumab ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Chronic Disease ; Dose-Response Relationship, Drug ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged ; Red-Cell Aplasia, Pure - drug therapy ; Remission Induction - methods ; Time Factors ; Treatment Outcome</subject><ispartof>Hong Kong medical journal = Xianggang yi xue za zhi, 2013-12, Vol.19 (6), p.549-552</ispartof><rights>2013. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.hkmj.org/about/website.html</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-39844d3f45c50ac47716a706474da462481627cb8fb3e720d00817255f8cb39b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,865,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24310664$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chow, Jason K W</creatorcontrib><creatorcontrib>Chan, T K</creatorcontrib><creatorcontrib>Department of Oncology, Charing Cross Hospital, Fulham Palace Road, London, United Kingdom</creatorcontrib><title>Low-dose subcutaneous alemtuzumab is a safe and effective treatment for chronic acquired pure red cell aplasia</title><title>Hong Kong medical journal = Xianggang yi xue za zhi</title><addtitle>Hong Kong Med J</addtitle><description>Three patients with pure red cell aplasia, with or without co-existing large granular lymphocytic leukaemia, who remained transfusion-dependent despite treatment with established first-line therapy, were treated with low-dose subcutaneous alemtuzumab 15 mg twice to thrice per week, for 3 to 4 weeks. The mean response time was 17 days compared with a response time of at least 61 days on standard first-line therapy. There were no serious side-effects and the mean duration of remission was 13 months. Low-dose subcutaneous alemtuzumab is a safe and effective treatment for pure red cell aplasia and further trials should be conducted to compare the long-term effectiveness of this treatment with conventional therapy.</description><subject>Aged</subject><subject>Alemtuzumab</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Chronic Disease</subject><subject>Dose-Response Relationship, Drug</subject><subject>Humans</subject><subject>Injections, Subcutaneous</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Red-Cell Aplasia, Pure - drug therapy</subject><subject>Remission Induction - methods</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1024-2708</issn><issn>2226-8707</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkUtLAzEUhYMotlZX7iXgRpDRvCbJLKX4goIbXQ-ZzA2dOq8mE0V_vVNbFVzde-HjcO45CJ1SckWZJtn18rVZUc5VpvfQlDEmE62I2kdTSphImCJ6go5CWBHCdJqRQzRhglMipZiidtG9J2UXAIdY2DiYFroYsKmhGeJnbEyBq_HEwTjApi0xOAd2qN4ADx7M0EA7YNd5bJe-ayuLjV3HykOJ--gBbxYLdY1NX5tQmWN04Ewd4GQ3Z-jl7vZ5_pAsnu4f5zeLxPJUDAnPtBAldyK1KTFWKEWlUUQKJUojJBOaSqZsoV3BQTFSEqKpYmnqtC14VvAZutjq9r5bRwhD3lRhY2T7X06FTLVMMy5G9Pwfuuqib0d3OVNaZmIMlI3U5ZayvgvBg8t7XzXGf-SU5N815H81jPTZTjMWDZS_7E_u_Au3CoKY</recordid><startdate>20131201</startdate><enddate>20131201</enddate><creator>Chow, Jason K W</creator><creator>Chan, T K</creator><general>Hong Kong Academy of Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BVBZV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20131201</creationdate><title>Low-dose subcutaneous alemtuzumab is a safe and effective treatment for chronic acquired pure red cell aplasia</title><author>Chow, Jason K W ; Chan, T K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-39844d3f45c50ac47716a706474da462481627cb8fb3e720d00817255f8cb39b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Alemtuzumab</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Chronic Disease</topic><topic>Dose-Response Relationship, Drug</topic><topic>Humans</topic><topic>Injections, Subcutaneous</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Red-Cell Aplasia, Pure - drug therapy</topic><topic>Remission Induction - methods</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chow, Jason K W</creatorcontrib><creatorcontrib>Chan, T K</creatorcontrib><creatorcontrib>Department of Oncology, Charing Cross Hospital, Fulham Palace Road, London, United Kingdom</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>East & South Asia Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Hong Kong medical journal = Xianggang yi xue za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chow, Jason K W</au><au>Chan, T K</au><aucorp>Department of Oncology, Charing Cross Hospital, Fulham Palace Road, London, United Kingdom</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low-dose subcutaneous alemtuzumab is a safe and effective treatment for chronic acquired pure red cell aplasia</atitle><jtitle>Hong Kong medical journal = Xianggang yi xue za zhi</jtitle><addtitle>Hong Kong Med J</addtitle><date>2013-12-01</date><risdate>2013</risdate><volume>19</volume><issue>6</issue><spage>549</spage><epage>552</epage><pages>549-552</pages><issn>1024-2708</issn><eissn>2226-8707</eissn><abstract>Three patients with pure red cell aplasia, with or without co-existing large granular lymphocytic leukaemia, who remained transfusion-dependent despite treatment with established first-line therapy, were treated with low-dose subcutaneous alemtuzumab 15 mg twice to thrice per week, for 3 to 4 weeks. The mean response time was 17 days compared with a response time of at least 61 days on standard first-line therapy. There were no serious side-effects and the mean duration of remission was 13 months. Low-dose subcutaneous alemtuzumab is a safe and effective treatment for pure red cell aplasia and further trials should be conducted to compare the long-term effectiveness of this treatment with conventional therapy.</abstract><cop>China</cop><pub>Hong Kong Academy of Medicine</pub><pmid>24310664</pmid><doi>10.12809/hkmj133798</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1024-2708 |
| ispartof | Hong Kong medical journal = Xianggang yi xue za zhi, 2013-12, Vol.19 (6), p.549-552 |
| issn | 1024-2708 2226-8707 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1465865934 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Alemtuzumab Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Chronic Disease Dose-Response Relationship, Drug Humans Injections, Subcutaneous Male Middle Aged Red-Cell Aplasia, Pure - drug therapy Remission Induction - methods Time Factors Treatment Outcome |
| title | Low-dose subcutaneous alemtuzumab is a safe and effective treatment for chronic acquired pure red cell aplasia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T11%3A30%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low-dose%20subcutaneous%20alemtuzumab%20is%20a%20safe%20and%20effective%20treatment%20for%20chronic%20acquired%20pure%20red%20cell%20aplasia&rft.jtitle=Hong%20Kong%20medical%20journal%20=%20Xianggang%20yi%20xue%20za%20zhi&rft.au=Chow,%20Jason%20K%20W&rft.aucorp=Department%20of%20Oncology,%20Charing%20Cross%20Hospital,%20Fulham%20Palace%20Road,%20London,%20United%20Kingdom&rft.date=2013-12-01&rft.volume=19&rft.issue=6&rft.spage=549&rft.epage=552&rft.pages=549-552&rft.issn=1024-2708&rft.eissn=2226-8707&rft_id=info:doi/10.12809/hkmj133798&rft_dat=%3Cproquest_cross%3E2786942262%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2786942262&rft_id=info:pmid/24310664&rfr_iscdi=true |